A Phase II, Multi-Center, Two-Tier Study of IMC-A12 in Combination with Depot Octreotide in Patients with Metastatic, Well- or Moderately-Differentiated Carcinoid or Islet Cell Carcinoma

Trial Profile

A Phase II, Multi-Center, Two-Tier Study of IMC-A12 in Combination with Depot Octreotide in Patients with Metastatic, Well- or Moderately-Differentiated Carcinoid or Islet Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Cixutumumab (Primary) ; Octreotide
  • Indications Carcinoid tumour; Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 01 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top